Wire · opportunities
Psychedelic Depression Treatments Are Gaining Attention – What Comes Next?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 November 2026 · Fusion42 review
Helus Pharma's psychedelic drug HLP003 showed rapid and durable symptom relief in a Phase 3 trial for major depressive disorder as an add-on to standard antidepressants, with over half of patients reaching remission within six weeks. The drug has FDA Breakthrough Therapy Designation but must still pass safety reviews and address adverse effects before approval.
This Wire brief sits within Fusion42's coverage of Mental Health.
◆ ◆ The Wire takeaway
Psychedelic depression treatments are moving beyond early trials into high-potential therapies that could disrupt daily pill routines. You must act fast to position your product as a safe, supervised alternative before regulators set new clinical standards.
◆ Coverage
1 source · 22 Nov 2026
◆ Related on Wire
◆ Topics